Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Halberd Corp
HALB
Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
New Post
OTCPK:HALB - Post by User
Halberd Corp
<< Previous
Bullboard Posts
Next >>
(58)
•••
badgirl007
X
View Profile
View Bullboard History
Post by
badgirl007
on Jul 28, 2021 9:05am
59 Views
Post# 33615741
YES YES - NEWS NEWS - greatest phantasy is not enough.
YES YES - NEWS NEWS - greatest phantasy is not enough.
“Never Before Accomplished”
Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”
A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE
Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating E. Coli bacteria through the use of its patent-pending laser emissive energy exposure technique. Recently, at Youngstown State University (YSU) and Arizona State University (ASU), the bacteria was mixed with a metallic nanoparticle complex, created through Halberd’s patent-pending process, designed to bind with the E. coli cells prior to exposing the mixture to laser energy. The testing, conducted by Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department at Youngstown State University, verified what is believed to be the first time a tuned laser has been successfully used to eradicate disease antigens.
Mitchell S. Felder, M.D., the co-inventor of this innovative technology, and the Chief Technology Officer of Halberd Corporation stated, “More than one out of four people on earth are destined to die from an infectious disease. Imagine a world where there is no threat from any infectious disease: no Covid-19, no malaria, no tuberculosis, no sepsis, no meningitis, no pandemics. The successful experimentation we have conducted in collaboration with Youngstown State University (YSU) and Arizona State University (ASU), may serve as the first step to an elegant solution to these worldwide tragedies.”
“By implementing our patent-pending extra-corporeal laser methodology, combined with the two granted U.S. patents of Halberd, along with the multiple provisional patent applications recently filed by the Ference law firm with co-inventors Dr. William Sturrus (YSU) and Dr. Qiang Chen (ASU), eradicating infectious diseases could become a reality.”
Felder continued, “Our method envisions utilizing a dialysis variation in which blood or spinal fluid are briefly removed from a patient, through a catheter, and then combined with antibodies which contain a metallic complex. The bodily fluid (blood, CSF: Cerebral Spinal Fluid) is then exposed to a laser or radio frequency (RF) energy, which kills the infectious pathogen. The cleansed (pathogen-/infection-free) bodily fluid is returned to the patient. Obviously, there will never be successful resistance by any infectious bacteria, virus or mutations, fungus or amoeba to a laser. This is entirely accomplished extracorporeally and without exposing the body to the effects of a laser.”
William A. Hartman, Halberd's Chairman, President & CEO, stated, “This is a clear breakthrough in the eradication of disease. Our extensive review of medical research reports reveals no other successful use of a laser for pathogen eradication. Over the next few weeks, we will apply what we learned in these E. coli experiments to eliminate from Cerebral Spinal Fluid the disease antigens comprising Alzheimer’s Disease and PTSD. In parallel, we will be conducting the initial RF exposure disease-elimination experiments, now that we have secured a more powerful RF generator. We expect our RF test results to mirror those displayed during our laser tests. This will be closely followed by proof-of-concept testing of our patent-pending Chemical Bonding Process. Having alternative treatment methods will offer health care professionals the flexibility to select the most suitable approach for each patient, disease condition and environment.”
https://halberdcorporation.com/news/
Comment on this Post
<< Previous
Bullboard Posts
Next >>
Nevada gold stock scores multiple high-grade hits
Amazon stock reaches for record highs after earnings report
Hempalta acquires controlling interest in Hemp Carbon Standard
Top-performing mining stock adds three new gold zones
Bombardier reveals NetJets as buyer behind US$6 billion order
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
{{ dialogTitle }}
×
Reject Reason
{{ policy.description }}
{{reasonError}}
Additional Comments
{{feedbackError}}
{{buttonTitle}}
Cancel
{{submitMsg}}
Featured News Links
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company